Breaking News
March 19, 2018 - Vitamin B12 supplementation could postpone disease progression in Parkinson’s patients
March 19, 2018 - Study shows that omega-6 fatty acids could protect against premature death
March 19, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
March 19, 2018 - Minorities More Sensitive To Pain? Pain Medicine News Report
March 19, 2018 - Low blood sugar poses unaddressed threat to people with type 2 diabetes
March 19, 2018 - ACEA goes live with exhaustive, searchable library of NovoCyte publications
March 19, 2018 - Consumption of low-calorie sweeteners could promote metabolic syndrome, increase diabetes risk
March 19, 2018 - Wearable medical patch shows promise for early detection of hypoglycemia in type 1 diabetes
March 19, 2018 - High-energy breakfast leads to better diabetes control and weight loss
March 19, 2018 - D.C. Week: Community Health Centers Get Azar’s Love
March 19, 2018 - Toothpaste alone does not prevent dental erosion or hypersensitivity
March 19, 2018 - Discovery aids understanding of amyotrophic lateral sclerosis
March 19, 2018 - Docs worry there’s ‘nowhere to send’ new and expectant moms with depression
March 19, 2018 - Obesity linked to increased DNA damage in breast epithelium of BRCA mutation carriers
March 19, 2018 - Heart rate increases with higher alcohol consumption
March 19, 2018 - Template produced for clinically validated DIY stethoscope
March 19, 2018 - Experts highlight nocturia as most common cause of poor night’s sleep
March 19, 2018 - Fit Middle-Aged Women May Fend Off Dementia Later
March 19, 2018 - Fake Insta Doc; Humana’s Weird Pay Bump Tax Trick; Few NPDB Searches
March 19, 2018 - Guidelines for fluoride intake—are they appropriate?
March 19, 2018 - Race and pre-pregnancy BMI may be key predictors of maternal weight gain
March 19, 2018 - Telediabetes program improves blood sugar control for veterans
March 19, 2018 - Research suggests breastfeeding as protective factor against obesity in high-birthweight infants
March 19, 2018 - Morning Break: House Nixes ‘Right-to-Try’ Bill; Purdue’s PR Makeover; Air in the Brain
March 19, 2018 - Heart researchers develop a new, promising imaging technique for cardiac arrhythmias
March 19, 2018 - Mice study shows how BPA exposure during pregnancy can lead to altered brain development
March 19, 2018 - Breastfeeding mothers who overeat may increase risk of health problems in offspring
March 19, 2018 - New mobile application can detect atrial fibrillation that causes strokes
March 19, 2018 - Study finds low rates of preconception counseling among women of childbearing age with diabetes
March 19, 2018 - Vitl Life Science Solutions announces launch of new Lu-mini at analytica 2018
March 19, 2018 - ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
March 19, 2018 - D.C. Week: States Plead for Federal $$ in Opioid Fight
March 19, 2018 - Polycystic ovary syndrome – Genetics Home Reference
March 19, 2018 - Reducing co-payments improves patient, physician adherence to guideline-recommended treatment post-MI
March 19, 2018 - Normalizing estrogen levels can benefit female athletes with irregular menstrual periods
March 19, 2018 - Fitness trackers and virtual coaches motivate patients to exercise post cardiac rehab
March 19, 2018 - Atrial fibrillation patients could reduce risk of dementia by taking stroke prevention drugs
March 19, 2018 - Low sperm count more prevalent with other health problems finds study
March 19, 2018 - Male birth control pill taken once a day shows success
March 19, 2018 - AcelRx Announces Receipt of Type A FDA Meeting Minutes and Plans to Resubmit the DSUVIA New Drug Application in Q2 2018
March 19, 2018 - Eye Docs Adopt EHRs Despite Reservations
March 19, 2018 - CRISPR enhances cancer immunotherapy
March 19, 2018 - Study finds first evidence of delayed aging among Americans
March 19, 2018 - Aussies unaware of sun protection rules to prevent skin cancer
March 19, 2018 - Essential oils linked to abnormal breast development in boys
March 19, 2018 - ‘Tummy Tuck’ Relieved Postpartum Back Pain/Incontinence
March 19, 2018 - New biomarkers for neuroblastoma, a type of cancer in children
March 19, 2018 - Hookah Smoking Carries a Poisoning Risk
March 19, 2018 - Do Mood and Anxiety Affect MS Disability?
March 19, 2018 - Mean depth of ultrasonographic penetration greater in autism
March 19, 2018 - Platypus milk may help combat antibiotic resistance
March 19, 2018 - U.S. IDE study of THERMOCOOL SMARTTOUCH SF Catheter completes patient enrollment
March 18, 2018 - E-cigarette use exposes adolescents to potentially cancer-causing chemicals
March 18, 2018 - GOP Senator: Solve Opioid Crisis Through Community, Not Policy
March 18, 2018 - Why is ADHD more common in boys than girls?
March 18, 2018 - Measles alert after two passengers with the disease fly into US
March 18, 2018 - FDA looks to remove nicotine from cigarettes
March 18, 2018 - FDA moves to cut nicotine in cigarettes, helping smokers kick habit
March 18, 2018 - Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis
March 18, 2018 - Surgery Tied to Better Outcomes in Kids with T2D
March 18, 2018 - Scientists use nanotechnology to detect molecular biomarker for osteoarthritis
March 18, 2018 - Research establishes use of chimeric cells as potential therapy for Duchenne muscular dystrophy
March 18, 2018 - Researcher working to develop improved endoscopic probe for colonoscopies
March 18, 2018 - Researchers develop way to sequence entire fetal genome by modifying prenatal testing method
March 18, 2018 - FDA Approves PDUFA Fee Waiver for Gimoti New Drug Application
March 18, 2018 - P2Y12 Tx Subsidy Yields Positive Response from Docs, Patients
March 18, 2018 - Are Proteins in Formula Linked to Type 1 Diabetes?
March 18, 2018 - Exercise does not seem to increase bone marrow edema in healthy people
March 18, 2018 - Researchers delineate architecture of nuclear pore complex in yeast cells
March 18, 2018 - ‘It’s Just Ghetto-izing People’: What We Heard This Week
March 18, 2018 - Alzheimer’s disease: Neuronal loss very limited
March 18, 2018 - Study reveals impact of intense, changing work schedules experienced by medical interns
March 18, 2018 - Jobs That Keep the Mind Sharp … Even Into Retirement
March 18, 2018 - Facial Scarring Improved with Botulinum Toxin
March 18, 2018 - Data detectives shift suspicions in Alzheimer’s to inside villain
March 18, 2018 - Shorter Preventive TB Tx Effective for HIV+ Patients
March 18, 2018 - New technique for identifying alcoholism puts treatment options at patients’ and providers’ fingertips
March 18, 2018 - Researchers uncover four microRNAs as potential biomarkers for atrial fibrillation
March 18, 2018 - IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
March 18, 2018 - OncoBreak: Learning from Silence; ‘Rigged’ Drug System; NCCN Guidelines Questioned
Combo Bests Targeted Agent in mRCC

Combo Bests Targeted Agent in mRCC

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and will be presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

SAN FRANCISCO — Patients with newly diagnosed metastatic renal cell carcinoma (mRCC) lived about 3 months longer without disease progression with immunotherapy-based treatment rather than a targeted agent, a randomized trial showed.

In the subgroup of patients with PD-L1 positive tumors, initial treatment with atezolizumab (Tecentriq) and bevacizumab (Avastin) led to a median progression-free survival (PFS) of 11.2 months compared with 7.7 months for patients who received standard first-line treatment with sunitinib (Sutent). The intention-to-treat population had a median PFS of 11.2 months with the combination and 8.4 months with sunitinib, according to Robert Motzer, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues.

Median overall survival (OS) in the ITT population had yet to be reached, but trended in favor of the atezolizumab-bevacizumab arm. Additionally, more patients had objective responses with the combination, Motzer reported at a press briefing prior to the Genitourinary Cancers Symposium (GUCS).

“The response outcomes and encouraging immature overall survival results support improved efficacy for atezolizumab plus bevacizumab in patients with PD-L1 positive disease,” said Motzer. “Atezolizumab and bevacizumab had fewer high-grade treatment-related adverse events, low steroid use, and delayed symptom interference with daily life versus sunitinib.

“These study results support the consideration of atezolizumab and bevacizumab as a first-line treatment option for PD-L1 positive patients with advanced renal cell carcinoma.”

The results “represent an important breakthrough in cancer therapy,” said press briefing moderator Sumanta Pal, MD, of City of Hope in Duarte, California. For several years, oncologists have debated the relative merits of immunotherapy and targeted therapy as the preferred treatment for advanced RCC.

“This study, which is the first of its kind, points to a combination of both as being highly effective in delaying cancer growth, and there’s also an early trend toward improving survival,” said Pal. “The higher rate of complete response with bevacizumab and atezolizumab was also very encouraging. Achieving a complete response — total eradication of metastatic disease — is really the highest bar that we can strive for in this setting.”

Tolerability with the combination of targeted and immune therapies is another important piece of information from the study, he added. The side effect profile appeared to be superior, in some respects, to that of oral targeted agents used in the setting of mRCC.

“I would agree with Dr. Motzer that the data support consideration of atezolizumab and bevacizumab as a first-line option,” said Pal.

The trial involved 915 patients with previously untreated mRCC. Investigators in the international multicenter trial randomized the patients to the combination of atezolizumab and bevacizumab or to sunitinib, which has been standard of care as first-line therapy for mRCC for the past decade, Motzer noted. About 40% of the patients tested positive for PD-L1 expression, defined as >1% expression on tumor-infiltrating immune cells.

The trial had co-primary endpoints of investigator-assessed PFS in the PD-L1 positive subgroup and OS in the ITT population. Secondary endpoints included PFS in the ITT population, objective response rate, and duration of response.

Motzer reported findings from an analysis performed after a median follow-up of 15 months. The 3.5-month difference in PFS in the PD-L1 positive group was associated with a hazard ratio of 0.74 in favor of the atezolizumab-bevacizumab combination (95% CI 0.57-0.96, P=0.0217). Immature survival data showed a 19% reduction in the HR in favor of the combination, although the median had yet to be reached in either arm (95% CI 0.63-1.03, P=0.09).

Other endpoints consistently favored the combination treatment:

  • PFS (ITT): 11.2 versus 8.4 months (HR 0.83, 95% CI 0.70-0.97, P=0.02)
  • Survival (PD-L1+): Not reached versus 23.3 months (HR 0.68, 95% CI 0.46-1.00, P=0.05)
  • Confirmed Response (PD-L1+): 43% versus 35%
  • Confirmed Response (ITT): 37% versus 33%
  • Complete Response (PD-L1+): 9% versus 4%
  • Complete Response (ITT): 5% versus 2%

The combination of an immune checkpoint inhibitor and angiogenesis inhibitor resulted in a better safety profile. Patients randomized to sunitinib had higher rates of diarrhea, palmar/plantar erythrodysesthesia, hypertension, fatigue, dysgeusia, decreased appetite, mucositis, stomatitis, asthenia, and vomiting. The combination was associated with more proteinuria. Motzer reported that 16% of patients in the combination arm required systemic steroids to manage adverse events.

The safety and efficacy of atezolizumab and bevacizumab compared favorably with the dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), which also has been evaluated in advanced RCC, Pal noted.

“That [dual immunotherapy] regimen also demonstrated improved outcomes relative to sunitinib in patients with newly diagnosed metastatic kidney cancer, but nearly 60% of patients required steroids for management of side effects as compared with 16% in the study reported by Dr. Motzer.”

The study was supported by Roche/Genentech.

Motzer disclosed relevant relationships with Pfizer, Novartis, Eisai, Exelisix, Merck, GlaxoSmithKline, Bristol-Myers Squibb, and Roche Genentech.


Tagged with:

About author

Related Articles